Staphylococcus aureus News and Research RSS Feed - Staphylococcus aureus News and Research

Staphylococcus aureus is a spherical bacterium (coccus) which on microscopic examination appears in pairs, short chains, or bunched, grape-like clusters. These organisms are Gram-positive. Some strains are capable of producing a highly heat-stable protein toxin that causes illness in humans.
Study identifies best course of treatment for endophthalmitis

Study identifies best course of treatment for endophthalmitis

The most common cause of endophthalmitis, a potentially blinding condition that can occur after eye trauma, eye surgery, and eye injections, are the well-known staphylococci ("staph") and streptococci ("strep") bacterial strains, according to a study published in the August issue of Ophthalmology and based on a review of 25 years of cases at New York Eye and Ear Infirmary of Mount Sinai (NYEE). [More]
Rectal and groin areas are frequent sites of colonization of community-associated MRSA

Rectal and groin areas are frequent sites of colonization of community-associated MRSA

Colonization of methicillin-resistant Staphylococcus aureus (MRSA) allows people in the community to unknowingly harbor and spread this life-threatening bacteria. [More]
TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS acquires novel antimicrobial drug candidates from Biota

TAXIS Pharmaceuticals, Inc. today announced the acquisition of a group of novel antimicrobial drug candidates from Biota Pharmaceuticals Inc. of Atlanta, GA. [More]
Discovery lays groundwork for new class of antibiotics for Staphylococcus aureus infections

Discovery lays groundwork for new class of antibiotics for Staphylococcus aureus infections

St. Jude Children's Research Hospital scientists have discovered an enzyme that regulates production of the toxins that contribute to potentially life-threatening Staphylococcus aureus infections. The study recently appeared in the scientific journal the Proceedings of the National Academy of Sciences. [More]
Research shows promise to speed up drug discovery for deadly diseases

Research shows promise to speed up drug discovery for deadly diseases

Antibiotic resistance is depleting our arsenal against deadly diseases and infections, such as tuberculosis and Staph infections, but recent research shows promise to speed up the drug discovery process. [More]
Scientists develop new weapon against bacterial infections in the form of tiny DNA pyramids

Scientists develop new weapon against bacterial infections in the form of tiny DNA pyramids

Bacterial infections usually announce themselves with pain and fever but often can be defeated with antibiotics - and then there are those that are sneaky and hard to beat. Now, scientists have built a new weapon against such pathogens in the form of tiny DNA pyramids. [More]
New research unit to uncover multi-drug resistant bacteria in hospitals

New research unit to uncover multi-drug resistant bacteria in hospitals

Multi-drug resistant bacteria have increased dramatically in hospitals in recent years and present immense challenges to staff and patients, often with fatal results. [More]
New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

New way to combat bacterial biofilm formation with titanium encrusted with gold nanoparticles

Bacteria love to colonize surfaces inside your body, but they have a hard time getting past your rugged, salty skin. [More]
Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Covenant and Sartori medical centers deploy TRU-D SmartUVC superbug-slaying robot

Wheaton Franciscan Healthcare-Iowa is the latest to deploy TRU-D SmartUVC, a 5-foot-5 germ-killing ultraviolet robot equipped with the only infection prevention data collection and reporting software on the market. TRU-D is now in use at Covenant Medical Center in Waterloo and Sartori Medical Center in Cedar Falls, Iowa. [More]
Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex testifies before U.S. House of Representatives on effectiveness of UV disinfection system in reducing HAI rates

Xenex Disinfection Services, the world leader in UV room disinfection systems, testified yesterday before the U.S. House of Representatives Committee on Science, Space, and Technology; Subcommittee on Research and Technology; and Subcommittee on Oversight. [More]
Personalized antibiotic therapy can help fight antibiotic-resistant infections

Personalized antibiotic therapy can help fight antibiotic-resistant infections

The Centers for Disease Control and Prevention warned last fall that the U.S. faces "potentially catastrophic consequences" if it doesn't act quickly to combat the growing threat of antibiotic-resistant infections, which kill about 23,000 Americans a year. [More]
Current sequencing protocols overlook DNA crucial to bacterial virulence

Current sequencing protocols overlook DNA crucial to bacterial virulence

Genomic sequencing is supposed to reveal the entire genetic makeup of an organism. For infectious disease specialists, the technology can be used to analyze a disease-causing bacterium to determine how much harm it is capable of causing and whether or not it will be resistant to antibiotics. [More]
Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals' SIVEXTRO receives FDA approval for treatment of ABSSSI

Cubist Pharmaceuticals, Inc. announced today the U.S. Food and Drug Administration approved SIVEXTRO (tedizolid phosphate) for the treatment of adult acute bacterial skin and skin structure infections (ABSSSI). [More]
Infection prevention and control guidance prioritizes strategies to combat MRSA

Infection prevention and control guidance prioritizes strategies to combat MRSA

New guidelines aim to reduce the prevalence of methicillin-resistant Staphylococcus aureus (MRSA), improve patient safety and prioritize current prevention efforts underway in hospitals. This drug resistant bacterium is a common source of patient morbidity and mortality in U.S. hospitals, causing nearly twice the number of deaths, significantly longer hospital stays and higher hospital costs than other forms of the bacteria. [More]
Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic, Enterome partner to study effects of beta-lactam antibiotics on gastrointestinal microflora

Synthetic Biologics, Inc., a developer of novel anti-infective biologic and drug candidates targeting specific pathogens that cause serious infections and diseases, and Enterome Bioscience SA, a pioneer in the development of innovative disease management solutions based on a deep understanding of the gut microbiome, today announced that they have entered into an agreement to conduct metagenomic research on the effects of beta-lactam antibiotics on the gastrointestinal microflora (microbiome) of human patients. [More]
S. pneumoniae is major cause of severe pneumonia in Gambian children

S. pneumoniae is major cause of severe pneumonia in Gambian children

Researchers have published a detailed survey of children with pneumonia in the Gambia, which reveals that Streptococcus pneumoniae is the predominant aetiological agent and that multiple pathogens are present in at least half of cases. [More]
Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals publishes positive results from Phase 3 clinical trial of SIVEXTRO

Cubist Pharmaceuticals, Inc. (NASDAQ: CBST) today announced that The Lancet Infectious Diseases published online the positive results from ESTABLISH-2, a pivotal Phase 3 clinical trial of the investigational antibiotic SIVEXTRO™ (tedizolid phosphate), which is being developed for the treatment of acute bacterial skin and skin structure infections (ABSSSI) and complicated skin and soft tissue infections (cSSTI). [More]
NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

NEJM publishes results from SOLO I Phase 3 clinical trial of ORBACTIV for ABSSSI

The Medicines Company today announced the publication of the results from the SOLO I Phase 3 clinical trial of ORBACTIV (oritavancin), an investigational intravenous antibiotic treatment for Acute Bacterial Skin and Skin Structure Infections (ABSSSI), in the New England Journal of Medicine. [More]

New single-dose antibiotic is as effective as twice-daily infusion given for up to 10 days

In the battle against stubborn skin infections, including methicillin-resistant Staphylococcus aureus (MRSA), a new single-dose antibiotic is as effective as a twice-daily infusion given for up to 10 days, according to a large study led by Duke Medicine researchers. [More]

New antibiotic proves effective in treating serious bacterial skin and skin-structure infections

A study published in today's New England Journal of Medicine reports that the antibiotic dalbavancin is as effective as vancomycin, the current standard-of-care antibiotic used to treat serious bacterial skin and skin-structure infections. [More]